Editas Medicine (EDIT) Short Interest Ratio & Short Volume $3.88 -0.26 (-6.28%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$3.92 +0.04 (+0.90%) As of 10/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Editas Medicine Short Interest DataEditas Medicine (EDIT) has a short interest of 7.46 million shares. This marks a -1.32% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.2, indicating that it would take 3.2 days of the average trading volume of 3.45 million shares to cover all short positions.Current Short Interest7,460,000 sharesPrevious Short Interest7,560,000 sharesChange Vs. Previous Month-1.32%Dollar Volume Sold Short$25.89 millionShort Interest Ratio3.2 Days to CoverLast Record DateSeptember 30, 2025Outstanding Shares89,920,000 sharesPercentage of Shares Shorted8.30%Today's Trading Volume2,542,282 sharesAverage Trading Volume3,445,801 sharesToday's Volume Vs. Average74% Short Selling Editas Medicine? Sign up to receive the latest short interest report for Editas Medicine and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEDIT Short Interest Over TimeEDIT Days to Cover Over TimeEDIT Percentage of Float Shorted Over Time Editas Medicine Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/30/20257,460,000 shares $25.89 million -1.3%N/A3.2 $3.47 9/15/20257,560,000 shares $20.19 million -3.3%N/A3.2 $2.67 8/31/20257,820,000 shares $20.10 million -4.6%8.9%3.2 $2.57 8/15/20258,200,000 shares $24.85 million +4.5%N/A3.3 $3.03 7/31/20257,850,000 shares $19.70 million -7.9%9.6%3.2 $2.51 7/15/20258,520,000 shares $23.43 million -2.4%N/A3.5 $2.75 6/30/20258,730,000 shares $19.21 million +3.6%10.7%3.6 $2.20 6/15/20258,430,000 shares $16.61 million -6.3%10.3%4 $1.97 5/31/20259,000,000 shares $15.62 million -1.0%11.1%4.6 $1.74 5/15/20259,090,000 shares $12.68 million -21.7%11.2%3.9 $1.40 Get the Latest News and Ratings for EDIT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. 4/30/202511,610,000 shares $19.16 million -8.4%N/A3.2 $1.65 4/15/202512,670,000 shares $17.10 million -0.1%15.6%3.5 $1.35 3/31/202512,680,000 shares $14.71 million -3.6%15.7%3.3 $1.16 3/15/202513,150,000 shares $19.20 million -4.5%16.2%3.4 $1.46 2/28/202513,770,000 shares $26.44 million -21.0%17.0%3.3 $1.92 2/15/202517,440,000 shares $24.07 million +2.1%21.5%4.4 $1.38 1/31/202517,090,000 shares $22.39 million -10.8%N/A6.6 $1.31 1/15/202519,150,000 shares $23.36 million +5.2%N/A7.1 $1.22 12/31/202418,210,000 shares $23.13 million +7.6%N/A7 $1.27 12/15/202416,930,000 shares $24.38 million +5.4%N/A6.9 $1.44 11/30/202416,060,000 shares $35.97 million +0.9%N/A7.2 $2.24 11/15/202415,910,000 shares $42.32 million -7.7%N/A7.4 $2.66 10/31/202417,240,000 shares $50.00 million -6.0%N/A8.8 $2.90 10/15/202418,330,000 shares $61.59 million +9.5%N/A9.9 $3.36 9/30/202416,740,000 shares $57.08 million -11.7%N/A9.3 $3.41 9/15/202418,960,000 shares $74.89 million +5.3%N/A10.5 $3.95 8/31/202418,010,000 shares $67.36 million +6.6%N/A9.4 $3.74 8/15/202416,900,000 shares $67.60 million +4.8%N/A8.5 $4.00 7/31/202416,130,000 shares $87.26 million +2.2%N/A7.7 $5.41 7/15/202415,790,000 shares $88.58 million -5.7%N/A7.6 $5.61 6/30/202416,740,000 shares $78.18 million -22.9%N/A8 $4.67 6/15/202421,700,000 shares $109.80 million -1.5%N/A10.6 $5.06 5/31/202422,020,000 shares $114.50 million +6.1%N/A11.7 $5.20 5/15/202420,760,000 shares $124.56 million +1.3%N/A10.3 $6.00 4/30/202420,500,000 shares $106.81 million +9.3%N/A10.3 $5.21 4/15/202418,760,000 shares $114.06 million +14.7%N/A9.8 $6.08 3/31/202416,360,000 shares $121.39 million +17.4%N/A8.9 $7.42 3/15/202413,930,000 shares $113.25 million +3.0%N/A7.5 $8.13 2/29/202413,520,000 shares $136.01 million +7.4%N/A7 $10.06 2/15/202412,590,000 shares $104.62 million +3.1%N/A7.2 $8.31 1/31/202412,210,000 shares $85.84 million -2.2%N/A6.7 $7.03 1/15/202412,480,000 shares $113.19 million -2.4%N/A6.8 $9.07 12/31/202312,790,000 shares $129.56 million -14.6%N/A7 $10.13 12/15/202314,970,000 shares $163.62 million -5.1%N/A7.7 $10.93 11/30/202315,780,000 shares $166.16 million -0.6%N/A8.9 $10.53 11/15/202315,870,000 shares $140.29 million -5.4%N/A9.7 $8.84 10/31/202316,770,000 shares $112.02 million +2.1%N/A11 $6.68 10/15/202316,420,000 shares $115.76 million +2.8%N/A11.2 $7.05 9/30/202315,970,000 shares $124.57 million +5.2%N/A11.1 $7.80 9/15/202315,180,000 shares $127.36 million +4.7%N/A10.8 $8.39 8/31/202314,500,000 shares $129.20 million +0.6%N/A8.1 $8.91 8/15/202314,410,000 shares $126.23 million -6.7%N/A7.5 $8.76 7/31/202315,440,000 shares $135.56 million -0.2%N/A7.5 $8.78 7/15/202315,470,000 shares $133.20 million -20.4%N/A7.4 $8.61 6/30/202319,430,000 shares $159.91 million -5.8%N/A8.6 $8.23 6/15/202320,630,000 shares $191.45 million +0.6%N/A9 $9.28 5/31/202320,500,000 shares $188.19 million +1.3%N/A11 $9.18 5/15/202320,230,000 shares $202.50 million +7.3%N/A11 $10.01 4/30/202318,860,000 shares $153.90 million -5.5%N/A10.7 $8.16 4/15/202319,950,000 shares $151.42 million +1.5%N/A11.1 $7.59 3/31/202319,650,000 shares $142.46 million -4.8%N/A11.3 $7.25 3/15/202320,640,000 shares $174.00 million +7.7%N/A11.9 $8.43 2/28/202319,160,000 shares $173.21 million -2.6%N/A10 $9.04 2/15/202319,670,000 shares $203.78 million -6.1%N/A10.2 $10.36 1/31/202320,940,000 shares $207.10 million -5.4%N/A10.5 $9.89 1/15/202322,140,000 shares $186.64 million +2.3%N/A11.8 $8.43 12/30/202221,650,000 shares $192.04 million +2.3%N/A12 $8.87 12/15/202221,170,000 shares $211.91 million +7.7%N/A12.3 $10.01 11/30/202219,650,000 shares $208.29 million +4.0%N/A11.7 $10.60 11/15/202218,900,000 shares $246.65 million +2.3%N/A12.1 $13.05 10/31/202218,470,000 shares $231.80 million -0.4%N/A12.1 $12.55 10/15/202218,540,000 shares $210.99 million +2.2%N/A11.8 $11.38 9/30/202218,150,000 shares $222.16 million +5.3%N/A11 $12.24 9/15/202217,240,000 shares $277.74 million +3.4%N/A10.1 $16.11 8/31/202216,680,000 shares $245.20 million +2.7%N/A9.6 $14.70 8/15/202216,250,000 shares $299.98 million -3.1%N/A9.3 $18.46 7/31/202216,770,000 shares $266.81 million +2.4%N/A9.5 $15.91 7/15/202216,380,000 shares $245.54 million +7.0%N/A9.3 $14.99 6/30/202215,310,000 shares $181.12 million +4.7%N/A9 $11.83 6/15/202214,620,000 shares $153.95 million +1.3%N/A8.8 $10.53 5/31/202214,430,000 shares $164.36 million +10.2%N/A9.1 $11.39 5/15/202213,090,000 shares $155.38 million +3.7%N/A7.7 $11.87 4/30/202212,620,000 shares $167.09 million +0.9%N/A7.3 $13.24 4/15/202212,510,000 shares $208.54 million +1.8%N/A6.9 $16.67 3/31/202212,290,000 shares $233.76 million +4.0%N/A6.5 $19.02 3/15/202211,820,000 shares $176.24 million +3.2%N/A6.3 $14.91 2/28/202211,450,000 shares $196.02 million +3.1%N/A6.1 $17.12 2/15/202211,110,000 shares $184.98 million +1.3%N/A6.1 $16.65 1/31/202210,970,000 shares $208.87 million -3.2%N/A6.5 $19.04 1/15/202211,330,000 shares $250.39 million -0.6%N/A7.8 $22.10 12/31/202111,400,000 shares $302.67 million +5.3%N/A8.8 $26.55 12/15/202110,830,000 shares $324.25 million +9.7%N/A6.9 $29.94 11/30/20219,870,000 shares $322.35 million +3.5%N/A6.7 $32.66 11/15/20219,540,000 shares $343.34 million -4.3%N/A6.4 $35.99 10/29/20219,970,000 shares $366.10 million -1.9%N/A6 $36.72 10/15/202110,160,000 shares $386.28 million +47.3%N/A5.8 $38.02 9/30/20216,900,000 shares $283.45 million -1.4%N/A3.9 $41.08 9/15/20217,000,000 shares $422.10 million +3.4%N/A3.5 $60.30 8/31/20216,770,000 shares $430.50 million -9.7%N/A3.5 $63.59 8/13/20217,500,000 shares $469.95 million -11.7%N/A4 $62.66 7/30/20218,490,000 shares $355.39 million +1.9%N/A4.7 $41.86 7/15/20218,330,000 shares $349.78 million -20.1%12.3%5 $41.99 6/30/202110,430,000 shares $590.76 million +0.6%15.4%5.9 $56.64 6/15/202110,370,000 shares $363.99 million -2.4%15.3%8 $35.10 5/28/202110,620,000 shares $360.55 million +0.9%15.7%7.9 $33.95 5/14/202110,530,000 shares $330.64 million +1.0%N/A6.2 $31.40 4/30/202110,430,000 shares $389.77 million +1.8%N/A5.3 $37.37 4/15/202110,250,000 shares $425.68 million +0.4%N/A4.7 $41.53 3/31/202110,210,000 shares $413.51 million -3.8%N/A4.1 $40.50 3/15/202110,610,000 shares $491.03 million -6.2%N/A3.7 $46.28 2/26/202111,310,000 shares $506.24 million +14.9%N/A3.5 $44.76 2/12/20219,840,000 shares $562.55 million +9.1%N/A3.3 $57.17 1/29/20219,020,000 shares $551.39 million -5.1%N/A3.4 $61.13 1/15/20219,500,000 shares $721.24 million -3.9%N/A3.9 $75.92 12/31/20209,890,000 shares $756.59 million -9.2%N/A4.8 $76.50 12/15/202010,890,000 shares $669.63 million -1.5%N/A6.4 $61.49 11/30/202011,060,000 shares $346.62 million -1.7%N/A10.2 $31.34 11/15/202011,250,000 shares $328.84 million -0.4%N/A12.9 $29.23 10/30/202011,290,000 shares $370.26 million -0.1%N/A13.6 $32.80 EDIT Short Interest - Frequently Asked Questions What is Editas Medicine's current short interest? Short interest is the volume of Editas Medicine shares that have been sold short but have not yet been covered or closed out. As of September 30th, traders have sold 7,460,000 shares of EDIT short. Learn More on Editas Medicine's current short interest. What is a good short interest ratio for Editas Medicine? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EDIT shares currently have a short interest ratio of 3.0. Learn More on Editas Medicine's short interest ratio. Which institutional investors are shorting Editas Medicine? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Editas Medicine: Group One Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Editas Medicine's short interest increasing or decreasing? Editas Medicine saw a decrease in short interest during the month of September. As of September 30th, there was short interest totaling 7,460,000 shares, a decrease of 1.3% from the previous total of 7,560,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Editas Medicine's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Editas Medicine: Beam Therapeutics Inc. (21.13%), CRISPR Therapeutics AG (23.47%), Intellia Therapeutics, Inc. (27.70%), Oric Pharmaceuticals, Inc. (11.57%), Spyre Therapeutics, Inc. (28.34%), Amylyx Pharmaceuticals, Inc. (12.64%), WAVE Life Sciences Ltd. (9.96%), Maze Therapeutics, Inc. (12.58%), Trevi Therapeutics, Inc. (12.18%), Immatics N.V. (2.85%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($15.71 billion), Robinhood Markets, Inc. ($7.56 billion), Reddit Inc. ($4.55 billion), Coinbase Global, Inc. ($4.53 billion), CoreWeave Inc. ($4.43 billion), Charter Communications, Inc. ($4.07 billion), Seagate Technology Holdings PLC ($3.94 billion), IonQ, Inc. ($3.78 billion), TC Energy Corporation ($3.13 billion), and Live Nation Entertainment, Inc. ($3.12 billion). View all of the most shorted stocks. What does it mean to sell short Editas Medicine stock? Short selling EDIT is an investing strategy that aims to generate trading profit from Editas Medicine as its price is falling. EDIT shares are trading down $0.26 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Editas Medicine? A short squeeze for Editas Medicine occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EDIT, which in turn drives the price of the stock up even further. How often is Editas Medicine's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EDIT, twice per month. The most recent reporting period available is September, 30 2025. More Short Interest Resources from MarketBeat Related Companies Beam Therapeutics Short Squeeze CRISPR Therapeutics Short Squeeze Intellia Therapeutics Short Squeeze Oric Pharmaceuticals Short Squeeze Spyre Therapeutics Short Squeeze Amylyx Pharmaceuticals Short Squeeze WAVE Life Sciences Short Squeeze Maze Therapeutics Short Squeeze Trevi Therapeutics Short Squeeze Immatics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EDIT) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredThe Republican party is falling apartSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
